Long-term relapses after 12-month treatment for Mycobacterium kansasii lung disease

European Respiratory Journal

Volumn 33, Issue 1, 2009, Pages 148-152

  Santin, M ^a   Dorca, J ^a   Alcaide, F ^a   Gonzalez, L ^a   Casas, S ^a   Lopez, M ^a   Guerra, M R ^a  

^a HOSPITAL UNIVERSITARI DE BELLVITGE   (Spain)

Author keywords

Mycobacterium kansasii; Relapse; Short treatment

Indexed keywords

ETHAMBUTOL; ISONIAZID; RIFAMPICIN; STREPTOMYCIN;

ADULT; AGED; ANTIBIOTIC RESISTANCE; ANTIBIOTIC THERAPY; ARTICLE; CONFIDENCE INTERVAL; CONTROLLED STUDY; DIZZINESS; DRUG DOSE REGIMEN; DRUG EFFICACY; DRUG HYPERSENSITIVITY; FEMALE; FOLLOW UP; HUMAN; LONG TERM CARE; LUNG INFECTION; MAJOR CLINICAL STUDY; MALE; MYCOBACTERIOSIS; MYCOBACTERIUM KANSASII; OBSERVATIONAL STUDY; PATIENT COMPLIANCE; PRIORITY JOURNAL; RECURRENCE RISK; RELAPSE; RETROSPECTIVE STUDY; SHORT COURSE THERAPY; TEACHING HOSPITAL; UNSPECIFIED SIDE EFFECT;

ADULT; ANTITUBERCULAR AGENTS; COHORT STUDIES; DRUG ADMINISTRATION SCHEDULE; DRUG THERAPY, COMBINATION; ETHAMBUTOL; FEMALE; HUMANS; ISONIAZID; LUNG DISEASES; MALE; MIDDLE AGED; MYCOBACTERIUM INFECTIONS, ATYPICAL; MYCOBACTERIUM KANSASII; RECURRENCE; RETROSPECTIVE STUDIES; RIFAMPIN; STREPTOMYCIN;

EID: 58849132874     PISSN: 09031936     EISSN: 13993003     Source Type: Journal    
DOI: 10.1183/09031936.00024008     Document Type: Article

References (23)

1. Wolinsky E. Nontuberculous mycobacteria and associated diseases. Am Rev Respir Dis 1979; 119: 107-159.
2. Bittner MJ, Horowitz EA, Safranek TJ, Preheim LC. Emergence of Mycobacterium kansasii as the leading mycobacterial pathogen isolated over a 20-year period at a midwestern Veterans Affairs hospital. Clin Infect Dis 1996; 22: 1109-1110.
3. Bloch KC, Zwerling L, Pletcher MJ, et al. Incidence and clinical implications of isolation of Mycobacterium kansasii: results of a 5-year, population-based study. Ann Intern Med 1998; 129: 698-704.
4. Griffith DE, Aksamit T, Brown-Elliott BA, et al. An official ATS/IDSA statement: diagnosis, treatment, and prevention of nontuberculous mycobacterial diseases. Am J Respir Crit Care Med 2007; 175: 367-416.
5. Pezzia W, Raleigh JW, Bailey MC, Toth EA, Silverblatt J. Treatment of pulmonary disease due to Mycobacterium kansasii: recent experience with rifampin. Rev Infect Dis 1981; 3: 1035-1039.
6. Ahn CH, Lowell JR, Ahn SS, Ahn S, Hurst GA. Chemotherapy for pulmonary disease due to Mycobacterium kansasii: efficacies of some individual drugs. Rev Infect Dis 1981; 3: 1028-1034.
7. Banks J, Hunter AM, Campbell IA, Jenkins PA, Smith AP. Pulmonary infection with Mycobacterium kansasii in Wales, 1970-9: review of treatment and response. Thorax 1983; 38: 271-274.
8. Pang SC. Mycobacterium kansasii infections in Western Australia (1962-1987). Respir Med 1991; 85: 213-218.
9. Management of opportunistic mycobacterial infections: Joint Tuberculosis Committee Guidelines 1999. Subcommittee of the Joint Tuberculosis Committee of the British Thoracic Society. Thorax 2000; 55: 210-218.
10. Ahn CH, Lowell JR, Ahn SS, Ahn SI, Hurst GA. Short-course chemotherapy for pulmonary disease caused by Mycobacterium kansasii. Am Rev Respir Dis 1983; 128: 1048-1050.
11. Schraufnagel DE, Stoner R, Whiting E, Snukst-Torbeck G, Werhane MJ. Testing for isoniazid. An evaluation of the Arkansas method. Chest 1990; 98: 314-316.
12. Gullans CR Sr. Digestion-decontamination procedures. In: Isenberg HD, ed. Clinical Microbiology Procedures Handbook. Washington, American Society for Microbiology, 1992: pp. 3.4.1-3.4.14.
13. Nolte FS, Metchock B. Mycobacterium. In: Murray PR, Baron EJ, Pfaller MA, Tenover FC, Yolken RH, eds. Manual of Clinical Microbiology. 6th Edn. Washington, American Society for Microbiology, 1995; pp. 400-437.
14. National Committee for Clinical Laboratory Standards. Susceptibility Testing of Mycobacteria, Nocardiae, and Other Aerobic Actinomycetes; Approved Standard. Document M24-A. Wayne, Clinical and Laboratory Standards Institute, 2003.
15. Inderlied CB, Nash KA. Antimycobacterial agents: in vitro susceptibility testing, spectra of activity,mechanisms of action and resistance, and assays for activity in biologic fluids. In: Lorian V, ed. Antibiotics in Laboratory Medicine. 4th Edn. Baltimore, Williams & Wilkins Co., 1996; pp. 127-175.
16. Inderlied CB, Pfyffer GE. Susceptibility test methods: Mycobacteria. In: Murray PR, Baron EJ, Jorgensen JH, Pfaller MA, Yolken RH, eds. Manual of Clinical Microbiology. 8th Edn. Washington, American Society for Microbiology, 2003; pp. 1149-1177.
17. Kaustová J, Chmelík M, Ettlová D, Hudec V, Lazarová H, Richtrová S. Disease due to Mycobacterium kansasii in the Czech Republic: 1984-89. Tuber Lung Dis 1995; 76: 205-209.
18. Sauret J, Hernández-Flix S, Castro E, Hernández L, Ausina V, Coll P. Treatment of pulmonary disease caused by Mycobacterium kansasii: results of 18 versus 12 months' chemotherapy. Tuber Lung Dis 1995; 76: 104-108.
19. Mycobacterium kansasii pulmonary infection: a prospective study of the results of nine months of treatment with rifampin and ethambutol. Research Committee, British Thoracic Society. Thorax 1994; 49: 442-445.
20. Alcaide F, Calatayud L, Santín M, Martín R. Comparative in vitro activities of linezolid, telithromycin, clarithromycin, levofloxacin, moxifloxacin, and four conventional antimycobacterial drugs against Mycobacterium kansasii. Antimicrob Agents Chemother 2004; 48: 4562-4565.
21. Guna R, Muñoz C, Domínguez V, et al. In vitro activity of linezolid, clarithromycin and moxifloxacin against clinical isolates of Mycobacterium kansasii. J Antimicrob Chemother 2005; 55: 950-953.
22. Cynamon MH, Elliott SA, DeStefano MS, Yeo AE. Activity of clarithromycin alone and in combination in a murine model of Mycobacterium kansasii infection. J Antimicrob Chemother 2003; 52: 306-307.
23. Griffith DE, Brown-Elliott BA, Wallace RJ Jr. Thrice-weekly clarithromycin-containing regimen for treatment of Mycobacterium kansasii lung disease: results of a preliminary study. Clin Infect Dis 2003; 37: 1178-1182.